VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic neuroplastogen in the treatment of psychiatric and neurological disorders, is issuing the following press release in response to British Columbia Securities Commission’s (“BCSC”) May 21, 2025 news release. BetterLife announced on July 16, 2024, that it had amended ...

LOS ALTOS, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will present at two upcoming virtual investment conferences. Event: Lytham Partners Spring 2025 Investor Conference Type: Fireside ChatDate/Time: Thursday, May 29, 2025, at 12:30 p.m. ET Event: Noble Capital Markets 2025 Emerging Growth Virtual Equity Con ...

Oslo, 22 May 2025. The Annual General Meeting in PCI Biotech Holding ASA took place today, 22 May 2025. All the matters on the agenda were approved and the minutes of the Annual General Meeting are attached to this release and are available on www.pcibiotech.com. Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CEO / CFO, rs@pcibiotech.no, Mobile: +47 9400 5757 This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securit ...

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 26, 2025 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The notice convening the annual general meeting stating the detailed agenda and modalities of participati ...

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 26, 2025 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The notice convening the annual general meeting stating the detailed agenda and modalities of participati ...

Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version inc ...

Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to ...

TrialWire™ 是基于 Salesforce Health Cloud 构建的风险共担、按招募人数计费、人工智能和算法驱动的患者招募平台，并提供行业领先的患者数据和知识产权安全保障旧金山, May 22, 2025 (GLOBE NEWSWIRE) -- TrialWire 今日宣布荣获 Fierce Biotech 主办的 Fierce CRO 奖项杰出患者招募与留存类目提名，闯入决赛。 TrialWire 是基于 Salesforce Health Cloud 构建的人工智能和算法驱动的患者招募和入组特色平台，具备一流的数据和知识产权安全保障。 该平台是一家风险共担、按招募人数计费的平台，可加速多语言、多文化背景下的全球研究和单一国家或区域性研究，以及混合式去中心化临床试验的开展。 TrialWire 平台专门设计了其主打产品 RapidRescue™，用于挽救各个停滞不前的临床试验。 点击此处预先登记您的研究，以备不时之需希望从一开始就获得招募确定性的申办方和合同研究组织 (CRO)，也可以借助 TrialWire 精心策划的定制患者注册解决方案 GeoClinical™，以加快研究机构启动并提高 ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Summary of Nuvation Bio Conference Call Company Overview - **Company**: Nuvation Bio - **Focus**: Development of innovative therapies, particularly in oncology, with a strong emphasis on ROS1 inhibition for non-small cell lung cancer [1][2] Key Points and Arguments Drug Development and FDA Approval - Nuvation Bio is on the verge of receiving FDA approval for its first drug, **telotrectinib**, a ROS1 inhibitor targeting ROS1-driven non-small cell lung cancers [3][4] - The New Drug Application (NDA) was submitted last year and accepted with priority review, with a PDUFA date set for **June 23** [4][9] - Telotrectinib shows an **overall response rate of 89%** and a **progression-free survival (PFS) of 46 months**, significantly outperforming standard care options [5][10] Patient Outcomes - The drug has demonstrated long-term PFS, with some patients remaining progression-free for **up to nine years** [6][10] - The average age of patients with ROS1 lung cancer is around **50 years**, with a significant number developing brain metastases early in the disease [4][5] Competitive Landscape - Nuvation Bio is the only ROS1 agent in development with **breakthrough designation** in both first and second-line settings [8][36] - The company has a robust safety database with over **400 patients** and a follow-up time of up to **nine years** [37] Market Opportunity - The potential market for telotrectinib is estimated at nearly **$4 billion annually** based on current DNA testing, with expectations to exceed **$5 billion** once RNA testing becomes standard [24][25] - The company anticipates commanding a significant share of this market due to its favorable drug profile [25] Launch Preparations - The commercial team is fully prepared for an immediate launch upon FDA approval, leveraging prior experience from successful launches at Medivation [18][20] - The team is confident in the drug's value proposition and market opportunity, despite acknowledging that launches can be challenging [23] Regulatory Changes - Recent updates to NCCN guidelines now contraindicate the use of immunotherapy for patients with ROS1 mutations, which is expected to shift treatment dynamics significantly [14][15] Pipeline and Future Developments - Nuvation Bio is also developing **safacitinib**, a mutant IDH1 inhibitor, which has shown promising response rates in glioma [39][40] - The company is exploring the potential of safacitinib as a new generation oral immuno-oncology agent [42] - The drug-drug conjugate platform, including candidate **1511**, is currently in clinical trials for various difficult-to-treat cancers [45] Financial Position - Nuvation Bio has **$62 million** on its balance sheet and expects to access an additional **$250 million** in non-dilutive capital upon approval [47] - The company is actively seeking new opportunities to bolster its pipeline, with a focus on innovative deals [48] Additional Important Insights - The launch in China has been positively received, with endorsements from medical organizations, indicating strong potential for international markets [32][33] - The company is committed to increasing awareness and testing rates for ROS1 mutations, which could further enhance patient identification and treatment rates [28][29] This summary encapsulates the critical insights from the Nuvation Bio conference call, highlighting the company's strategic positioning, drug development progress, and market opportunities.